Dr. Sangtae Kim to Lead Verseon's New AI and Data-Science Initiative as CTO
Retrieved on:
Wednesday, January 12, 2022
Biological engineering, Chemical engineering, Research, CTO, BS, NSF, American Institute of Chemical Engineers, Science, Collection, Ho-Am Prize in Engineering, Morgridge Institute for Research, CEO, American Institute for Medical and Biological Engineering, Drug design, Hereditary angioedema, Government, Eli Lilly, Lists of diseases, Distinguishing, Initiative, Warner–Lambert, Ho-Am Prize in Science, National Academy of Engineering, University of Wisconsin–Madison, American Institute, William O. Baker Award for Initiatives in Research, Drug development, Doctor of Philosophy, National, AI, Verseon, Medicine, National academy, Sang, University, Diabetic retinopathy, Microfluidics, Pharmaceutical industry, Management, Engineering, Purdue University, California Institute of Technology
FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.
Key Points:
- FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.
- Sang, a member of the US National Academy of Engineering , will spearhead expansion of the company's data-science and AI initiatives.
- Sang's engineering and data-science expertise will both complement and expand Verseon's already significant technological advantages in computer-driven drug design.
- In recent years he has started research initiatives to use AI for multiple aspects of drug design and development.